
Low Dose Naltrexone: Relief from Painful Symptoms and Autoimmune Diseases
Discover how Low Dose Naltrexone (LDN) can improve autoimmune diseases and relieve painful symptoms associated with inflammation, as well as learn about its usage, benefits, and side effects.
What is Low Dose Naltrexone (LDN)?
- Initially designed as an opioid antagonist for addiction treatment
- FDA-approved in 1984 at 50mg doses
- LDN is a smaller dose (1.5mg to 4.5mg) found to improve autoimmune diseases and chronic pain
How LDN Works:
- Binds and blocks opioid receptors, increasing endorphin production and modulating the immune system
- Binds and blocks Toll-like receptors, reducing inflammation
Commonly Treated Conditions:
- Hashimoto’s Disease
- Rheumatoid Arthritis
- Chronic Fatigue Syndrome
- Fibromyalgia
- Ulcerative Colitis
- Crohn’s Disease
- Multiple Sclerosis
- Celiac Disease
- Psoriasis
- Sjogren’s
- Scleroderma
- Lyme Disease
LDN Dosing:
- A gradual increase in dose each week; how quickly depends on the treated disease
Side Effects:
- Generally well-tolerated
- May result in a need to lower the thyroid dose in patients with Hashimoto’s Dz.
- Occasional headaches or vivid dreams when taken at bedtime (less than 10%)
- Insomnia (usually resolves within two weeks or by switching to morning regimen)
How Long Does LDN Take to Work?
- It depends on the disease and how quickly you work up to the appropriate dosage.
- When used for pain relief, within the first 2-3 months
- Not a substitute for standard treatments but used as an adjunct to other therapies.
Why Traditional Doctors May Not Prescribe LDN:
- Limited knowledge of LDN’s usage for autoimmune diseases
- Lack of extensive studies funded by drug companies
For more information or to schedule a consultation with Dr. Scott, call 704-282-9355. Remember that LDN may take time to make a noticeable difference in your symptoms. Still, with continued treatment, you can experience a decrease in inflammation, relief from pain, and overall symptom improvement. Ready to purchase LDN? COMING SOON!